A single-blind, randomized, placebo controlled, ascending single and repeat dose study with once daily dosing to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK376501 and to evaluate food effects and the relative bioavailability of a tablet formulation compared to the powder for reconstitution formulation in healthy overweight and obese subjects (DIX109177).

Trial Profile

A single-blind, randomized, placebo controlled, ascending single and repeat dose study with once daily dosing to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK376501 and to evaluate food effects and the relative bioavailability of a tablet formulation compared to the powder for reconstitution formulation in healthy overweight and obese subjects (DIX109177).

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs GSK 376501 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Aug 2007 Status changed from recruiting to completed.
    • 07 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top